Since early studies assessing BRAF inhibitors as monotherapy have shown limited activity, recent trials have been focused on the dual inhibition of BRAF and MEK, trying to translate previous evidence for other malignancies, such as metastatic melanoma, in this setting [77]. Here, BRAF is linked to metastatic melanoma.